These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26468683)

  • 1. The Effect of Buprenorphine on Methamphetamine Cravings.
    Salehi M; Emadossadat A; Kheirabadi GR; Maracy MR; Sharbafchi MR
    J Clin Psychopharmacol; 2015 Dec; 35(6):724-7. PubMed ID: 26468683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Add-on Buprenorphine to Matrix Program in Reduction of Craving and Relapse Among People With Methamphetamine Use Disorder: A Randomized Controlled Trial.
    Kheirabadi GR; Bahrami M; Shariat A; Tarrahi M
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):45-48. PubMed ID: 33347022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study.
    Mousavi SG; Sharbafchi MR; Salehi M; Peykanpour M; Karimian Sichani N; Maracy M
    Arch Iran Med; 2015 Jan; 18(1):28-33. PubMed ID: 25556383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial.
    Kheirabadi GR; Ghavami M; Maracy MR; Salehi M; Sharbafchi MR
    Adv Biomed Res; 2016; 5():149. PubMed ID: 27656618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial.
    Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K
    Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
    Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
    Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder.
    Aryan N; Banafshe HR; Farnia V; Shakeri J; Alikhani M; Rahimi H; Sehat M; Mamsharifi P; Ghaderi A; Omidi A
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):72. PubMed ID: 32977820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
    Rezaei F; Emami M; Zahed S; Morabbi MJ; Farahzadi M; Akhondzadeh S
    Daru; 2015 Jan; 23(1):2. PubMed ID: 25588930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
    McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
    Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial.
    Farahzadi MH; Moazen-Zadeh E; Razaghi E; Zarrindast MR; Bidaki R; Akhondzadeh S
    J Psychopharmacol; 2019 Mar; 33(3):305-315. PubMed ID: 30526230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy.
    Rabiey A; Hassani-Abharian P; Farhad M; Moravveji AR; Akasheh G; Banafshe HR
    Arch Iran Med; 2019 Dec; 22(12):692-698. PubMed ID: 31823620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
    Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
    Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence.
    Longo M; Wickes W; Smout M; Harrison S; Cahill S; White JM
    Addiction; 2010 Jan; 105(1):146-54. PubMed ID: 19839966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
    Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
    Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction.
    Li MD; Wang J; Niu T; Ma JZ; Seneviratne C; Ait-Daoud N; Saadvandi J; Morris R; Weiss D; Campbell J; Haning W; Mawhinney DJ; Weis D; McCann M; Stock C; Kahn R; Iturriaga E; Yu E; Elkashef A; Johnson BA
    BMC Med Genomics; 2014 Dec; 7():65. PubMed ID: 25495887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
    Shearer J; Darke S; Rodgers C; Slade T; van Beek I; Lewis J; Brady D; McKetin R; Mattick RP; Wodak A
    Addiction; 2009 Feb; 104(2):224-33. PubMed ID: 19149817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.